Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE versus CARBOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE versus CARBOCAINE.
BUPIVACAINE HYDROCHLORIDE vs CARBOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine hydrochloride is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the generation and propagation of action potentials and producing reversible local anesthesia.
Mepivacaine, the active ingredient in Carbocaine, is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses.
0.25% to 0.5% solution infiltrated locally, up to 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000) per dose; maximum 400 mg per 24 hours. For epidural: 0.5% to 0.75% solution, 15-20 mL for surgical anesthesia.
1% to 2% solution, 5-20 mL local infiltration or nerve block; maximum dose 400 mg (or 7 mg/kg) per 90-minute period.
None Documented
None Documented
Terminal elimination half-life: 2.7 hours (adults); prolonged in neonates (8.1 hours) and patients with hepatic impairment; clinical context: half-life increases with repeated dosing due to accumulation.
2.0–3.5 hours in adults; prolonged in patients with hepatic impairment (up to 8–10 hours) or renal dysfunction.
Primarily hepatic metabolism (CYP3A4, CYP1A2, and amidases) to pipecoloxylidine and desbutylbupivacaine; less than 5% excreted unchanged in urine; negligible biliary/fecal excretion.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination, with less than 5% excreted in feces via biliary elimination.
Category C
Category C
Local Anesthetic
Local Anesthetic